Biologic brachytherapy: Ex vivo transduction of microvascular beds for efficient, targeted gene therapy

Joseph Michaels, Jamie P. Levine, Alexes Hazen, Daniel J. Ceradini, Robert D. Galiano, Hooman Soltanian, Geoffrey C. Gurtner

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Gene therapy for cancer holds enormous therapeutic promise, but its clinical application has been limited by the inability to achieve targeted, high-level transgene expression with limited systemic toxicity. The authors have developed a novel method for delivering genes to microvascular free flaps (commonly used during reconstructive surgery) to avoid these problems. METHODS: During the finite period in which a free flap is separated from the host (ex vivo), it can be perfused with extremely high titers of genetic material through the afferent artery, resulting in efficient transduction of the tissue. Before reanastomosis, unincorporated genetic material is flushed from the flap, minimizing systemic toxicity. RESULTS: In a rodent model using an adenoviral vector containing the lacZ reporter gene, high regional expression of β-galactosidase was achieved in all the different cells in a microvascular free flap. Moreover, no β-galactosidase staining was observed outside of the transduced flap, and viral sequence was undetectable by polymerase chain reaction analysis in other tissues. Further analysis confirmed that high-level transgene expression was precisely localized to the explanted tissue, with no collateral transduction. CONCLUSIONS: Targeting gene delivery with minimal systemic toxicity is essential for successful gene therapy. This form of "biological brachytherapy" provides a new opportunity to deliver targeted therapeutic transgenes to patients undergoing reconstructive surgery and allows microvascular free flaps to perform therapeutic and reconstructive functions.

Original languageEnglish (US)
Pages (from-to)54-65
Number of pages12
JournalPlastic and Reconstructive Surgery
Volume118
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Free Tissue Flaps
Brachytherapy
Genetic Therapy
Reconstructive Surgical Procedures
Transgenes
Galactosidases
Genes
Lac Operon
Gene Targeting
Essential Genes
Reporter Genes
Rodentia
Therapeutics
Arteries
Staining and Labeling
Polymerase Chain Reaction
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Biologic brachytherapy : Ex vivo transduction of microvascular beds for efficient, targeted gene therapy. / Michaels, Joseph; Levine, Jamie P.; Hazen, Alexes; Ceradini, Daniel J.; Galiano, Robert D.; Soltanian, Hooman; Gurtner, Geoffrey C.

In: Plastic and Reconstructive Surgery, Vol. 118, No. 1, 01.07.2006, p. 54-65.

Research output: Contribution to journalArticle

Michaels, Joseph ; Levine, Jamie P. ; Hazen, Alexes ; Ceradini, Daniel J. ; Galiano, Robert D. ; Soltanian, Hooman ; Gurtner, Geoffrey C. / Biologic brachytherapy : Ex vivo transduction of microvascular beds for efficient, targeted gene therapy. In: Plastic and Reconstructive Surgery. 2006 ; Vol. 118, No. 1. pp. 54-65.
@article{071befa77573450ea35a20e01ce6cffc,
title = "Biologic brachytherapy: Ex vivo transduction of microvascular beds for efficient, targeted gene therapy",
abstract = "BACKGROUND: Gene therapy for cancer holds enormous therapeutic promise, but its clinical application has been limited by the inability to achieve targeted, high-level transgene expression with limited systemic toxicity. The authors have developed a novel method for delivering genes to microvascular free flaps (commonly used during reconstructive surgery) to avoid these problems. METHODS: During the finite period in which a free flap is separated from the host (ex vivo), it can be perfused with extremely high titers of genetic material through the afferent artery, resulting in efficient transduction of the tissue. Before reanastomosis, unincorporated genetic material is flushed from the flap, minimizing systemic toxicity. RESULTS: In a rodent model using an adenoviral vector containing the lacZ reporter gene, high regional expression of β-galactosidase was achieved in all the different cells in a microvascular free flap. Moreover, no β-galactosidase staining was observed outside of the transduced flap, and viral sequence was undetectable by polymerase chain reaction analysis in other tissues. Further analysis confirmed that high-level transgene expression was precisely localized to the explanted tissue, with no collateral transduction. CONCLUSIONS: Targeting gene delivery with minimal systemic toxicity is essential for successful gene therapy. This form of {"}biological brachytherapy{"} provides a new opportunity to deliver targeted therapeutic transgenes to patients undergoing reconstructive surgery and allows microvascular free flaps to perform therapeutic and reconstructive functions.",
author = "Joseph Michaels and Levine, {Jamie P.} and Alexes Hazen and Ceradini, {Daniel J.} and Galiano, {Robert D.} and Hooman Soltanian and Gurtner, {Geoffrey C.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/01.prs.0000220466.27521.22",
language = "English (US)",
volume = "118",
pages = "54--65",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Biologic brachytherapy

T2 - Ex vivo transduction of microvascular beds for efficient, targeted gene therapy

AU - Michaels, Joseph

AU - Levine, Jamie P.

AU - Hazen, Alexes

AU - Ceradini, Daniel J.

AU - Galiano, Robert D.

AU - Soltanian, Hooman

AU - Gurtner, Geoffrey C.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - BACKGROUND: Gene therapy for cancer holds enormous therapeutic promise, but its clinical application has been limited by the inability to achieve targeted, high-level transgene expression with limited systemic toxicity. The authors have developed a novel method for delivering genes to microvascular free flaps (commonly used during reconstructive surgery) to avoid these problems. METHODS: During the finite period in which a free flap is separated from the host (ex vivo), it can be perfused with extremely high titers of genetic material through the afferent artery, resulting in efficient transduction of the tissue. Before reanastomosis, unincorporated genetic material is flushed from the flap, minimizing systemic toxicity. RESULTS: In a rodent model using an adenoviral vector containing the lacZ reporter gene, high regional expression of β-galactosidase was achieved in all the different cells in a microvascular free flap. Moreover, no β-galactosidase staining was observed outside of the transduced flap, and viral sequence was undetectable by polymerase chain reaction analysis in other tissues. Further analysis confirmed that high-level transgene expression was precisely localized to the explanted tissue, with no collateral transduction. CONCLUSIONS: Targeting gene delivery with minimal systemic toxicity is essential for successful gene therapy. This form of "biological brachytherapy" provides a new opportunity to deliver targeted therapeutic transgenes to patients undergoing reconstructive surgery and allows microvascular free flaps to perform therapeutic and reconstructive functions.

AB - BACKGROUND: Gene therapy for cancer holds enormous therapeutic promise, but its clinical application has been limited by the inability to achieve targeted, high-level transgene expression with limited systemic toxicity. The authors have developed a novel method for delivering genes to microvascular free flaps (commonly used during reconstructive surgery) to avoid these problems. METHODS: During the finite period in which a free flap is separated from the host (ex vivo), it can be perfused with extremely high titers of genetic material through the afferent artery, resulting in efficient transduction of the tissue. Before reanastomosis, unincorporated genetic material is flushed from the flap, minimizing systemic toxicity. RESULTS: In a rodent model using an adenoviral vector containing the lacZ reporter gene, high regional expression of β-galactosidase was achieved in all the different cells in a microvascular free flap. Moreover, no β-galactosidase staining was observed outside of the transduced flap, and viral sequence was undetectable by polymerase chain reaction analysis in other tissues. Further analysis confirmed that high-level transgene expression was precisely localized to the explanted tissue, with no collateral transduction. CONCLUSIONS: Targeting gene delivery with minimal systemic toxicity is essential for successful gene therapy. This form of "biological brachytherapy" provides a new opportunity to deliver targeted therapeutic transgenes to patients undergoing reconstructive surgery and allows microvascular free flaps to perform therapeutic and reconstructive functions.

UR - http://www.scopus.com/inward/record.url?scp=33746858150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746858150&partnerID=8YFLogxK

U2 - 10.1097/01.prs.0000220466.27521.22

DO - 10.1097/01.prs.0000220466.27521.22

M3 - Article

C2 - 16816674

AN - SCOPUS:33746858150

VL - 118

SP - 54

EP - 65

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 1

ER -